Overexpression of the EMT driver brachyury in breast carcinomas: Association with poor prognosis

Journal of the National Cancer Institute

Volumn 106, Issue 5, 2014, Pages

  Palena, Claudia ^a   Roselli, Mario ^b   Litzinger, Mary T ^a   Ferroni, Patrizia ^c   Costarelli, Leopoldo ^d   Spila, Antonella ^c   Cavaliere, Francesco ^e   Huang, Bruce ^a   Fernando, Romaine I ^a   Hamilton, Duane H ^a   Jochems, Caroline ^a   Tsang, Kwong Yok ^a   Cheng, Qing ^f   Lyerly, H Kim ^f   Schlom, Jeffrey ^a   Guadagni, Fiorella ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d Department of Pathology ^*  (Italy)

^e SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MESSENGER RNA; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BRACHYURY; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISTANT METASTASIS; DRUG CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; TUMOR INVASION; TUMOR RESISTANCE; VERY ELDERLY;

EID: 84905171394     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju054     Document Type: Article

References (47)

1. Thiery JP, Sleeman J P. Complex networks orchestrate epithelial-mesen- chymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-142.
2. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-1428.
3. Thiery J P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442-454.
4. Polyak K, Weinberg RA. Transitions between epithelial and mesenchy-mal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265-273.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
6. Blick T, Widodo E, Hugo H, et al. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis. 2008;25(6):629-642.
7. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, et al. Epithelial-mesenchy- mal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68(4):989-997.
8. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009;106(33):13820-13825.
9. Kispert A, Koschorz B, Herrmann BG. The T protein encoded by Brachyury is a tissue-specific transcription factor. EMBO J. 1995;14(19):4763-4772.
10. Edwards YH, Putt W, Lekoape KM, et al. The human homolog T of the mouse T(Brachyury) gene; gene structure, cDNA sequence, and assignment to chromosome 6q27. Genome Res. 1996;6(3):226-233.
11. Fernando RI, Litzinger M, Trono P, et al. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest. 2010;120(2):533-544.
12. Fernando RI, Castillo MD, Litzinger M, et al. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011;71(15):5296-5306.
13. Palena C, Polev DE, Tsang KY, et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res. 2007;13(8):2471-2478.
14. Roselli M, Fernando RI, Guadagni F, et al. Brachyury, a driver of the epi-thelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res. 2012;18(14):3868-3879.
15. ClinicalTrials.gov. Open label study to evaluate the safety and tolerabil-ity of GI-6301 a vaccine consisting of whole heat-killed recombitant yeast genetically modified to express brachyury protein in adults with solid tumors. http://www.clinicaltrials.gov/ct2/show/NCT01519817. Accessed February 25, 2014.
16. College of American Pathologists. HER2 testing guidelines and resources. http://www.cap.org/apps/cap.portal. Accessed February 25, 2014.
17. Cheng Q, Chang JT, Geradts J, et al. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. 2012;14(2):R62
18. Anderson WF, Chu KC, Chatterjee N, et al. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol. 2001;19(1):18-27.
19. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21(10):1973-1979.
20. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
21. Darb-Esfahani S, Loibl S, Muller BM, et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 2009;11(5):R69.
22. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24(7):1037-1044.
23. Blanco MJ, Moreno-Bueno G, Sarrio D, et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene. 2002;21(20):3241-3246.
24. Elloul S, Elstrand MB, Nesland JM, et al. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005;103(8):1631-1643.
25. Come C, Magnino F, Bibeau F, et al. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res. 2006;12(18):5395-5402.
26. Martin TA, Goyal A, Watkins G, et al. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol. 2005;12(6):488-496.
27. Mironchik Y, Winnard PT, Jr., Vesuna F, et al. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res. 2005;65(23):10801-10809.
28. Wang SM, Coljee VW, Pignolo RJ, et al. Cloning of the human twist gene: its expression is retained in adult mesodermally-derived tissues. Gene. 1997;187(1):83-92.
29. Paznekas WA, Okajima K, Schertzer M, et al. Genomic organization, expression, and chromosome location of the human SNAIL gene (SNAI1) and a related processed pseudogene (SNAI1P). Genomics. 1999;62(1):42-49.
30. Desmedt C, Giobbie-Hurder A, Neven P, et al. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics. 2009;2:40.
31. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25(10):1239-1246.
32. Loi S, Haibe-Kains B, Majjaj S, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA. 2010;107(22):10208- 10213.
33. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;13(11):3207- 3214.
34. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365(9460):671-679.
35. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, et al. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol. 2007;20(4):474-481.
36. Lengerke C, Fehm T, Kurth R, et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer. 2011;11:42.
37. Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a pox-viral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501-508.
38. Jacobs JJ, Keblusek P, Robanus-Maandag E, et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet. 2000;26(3):291-299.
39. Fan W, Huang X, Chen C, et al. TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Cancer Res. 2004;64(15):5132-5139.
40. Yarosh W, Barrientos T, Esmailpour T, et al. TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacety-lases. Cancer Res. 2008;68(3):693-699.
41. Wang B, Lindley LE, Fernandez-Vega V, et al. The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells. PLoS One. 2012;7(7):e41355.
42. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 2006;209(2):157-165.
43. Tirabosco R, Mangham DC, Rosenberg AE, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 2008;32(4):572-580.
44. O'Donnell P, Tirabosco R, Vujovic S, et al. Diagnosing an extra-axial chor-doma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation. Skeletal Radiol. 2007;36(1):59-65.
45. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-715.
46. Huang B, Cohen JR, Fernando RI, et al. The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death Dis. 2013;4:e682.
47. Sims AH, Howell A, Howell SJ, et al. Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol. 2007;4(9):516-525.